Appointment of Broker

RNS Number : 1048Y

Nuformix PLC

01 December 2017

 

Nuformix plc

("Nuformix" or "the Company")

Appointment of Broker

Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, is pleased to announce the appointment of Beaufort Securities Limited as the Company's broker.

Follow Nuformix on Vox Markets: follow at www.voxmarkets.co.uk/company/NFX

and www.nuformix.com

ENDS

Enquiries:

Nuformix plc Dan Gooding, Chief Executive Officer	[phone]
Beaufort Securities Limited (Joint Broker) Jon Belliss	[phone]
Gable Communications Ltd John Bick / Justine James	[phone]

About Nuformix plc  www.nuformix.com 

Nuformix is a pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs.   Nuformix' risk-mitigated development strategy has resulted in a pipeline of discoveries through which it has developed and patented novel cocrystal forms of approved small molecules.

Nuformix has created an IP portfolio containing a range of granted patents covering cocrystal forms of five small molecule drugs.  Nuformix is targeting high-value unmet needs with its lead programmes in oncology supportive care: NXP001 and fibrosis: NXP002.

Nuformix was established in Cambridge in 2008 and has invested into pharmaceutical cocrystal R&D, establishing world-class capability and know-how in cocrystal discovery and development, yielding multiple product opportunities.  Nuformix plc shares are traded on the London Stock Exchange's Official List under the ticker: NFX.L.

 

END

 

 

APPFSWSWFFWSEEE